{"id":49517,"date":"2018-10-22T00:00:00","date_gmt":"2018-10-21T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/"},"modified":"2020-11-18T14:55:36","modified_gmt":"2020-11-18T13:55:36","slug":"aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/","title":{"rendered":"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure"},"content":{"rendered":"

The collaboration will enable the conduct of a clinical study, entitled AELIX-003, to investigate the safety, tolerability, immunogenicity and efficacy of a regimen containing AELIX Therapeutics\u2019\u00a0HTI T-cell vaccine<\/a>\u00a0and Gilead\u00b4s Toll-Like Receptor 7 agonist Vesatolimod<\/a>,\u00a0a\u00a0selective oral TLR7 agonist that directly\u00a0activates plasmacytoid dendritic cells.\u00a0\u00a0<\/span><\/p>\n

The vaccine\u2019s HTI immunogen contains specific HIV antigenic regions toward which there is an enriched T-cell immune response in those individuals who have \u201ccontroller phenotypes\u201d, meaning they can control the HIV to a large extent without taking antiretroviral drugs. The HTI vaccine is aimed at refocusing the immune response to especially vulnerable sites in HIV, including viruses activated from reservoirs.\u00a0n this study, Vesatolimod is expected to activate\u00a0expression of HIV in the body, and to enhance the vaccine-induced immune response leading to the elimination of virus-infected cells. agonist vesatolimod in HIV-infected individuals on antiretroviral therapy.<\/p>\n

\u201cThis collaboration brings together Gilead\u00b4s extensive experience in antiviral drug development with our highly innovative vaccine platform\u201d commented Dr Ian McGowan, VP Medical Affairs of AELIX.<\/p>\n

\u201cMaintenance of viral remission without antiretroviral therapy represents the next frontier in HIV treatment. We are excited to be collaborating with Gilead on this project, our first step to show the potential of our HTI immunogen as the backbone of combination regimens for maintenance of viral remission\u201d, said Dr Lance Berman, AELIX\u00b4s recently appointed Chief Medical Officer. \u201cGilead is committed to the research and development of new therapies that may help inform potential cure strategies for people living with HIV,\u201d said John McHutchison, AO, MD, Chief Scientific Officer, Gilead Sciences.<\/p>\n

\u201cThis collaboration will bring together two promising investigational agents that are already being tested independently in early-stage trials. Gilead looks forward to working with AELIX Therapeutics on this innovative clinical research effort.\u201d\u00a0<\/p>\n

\u25baMore information: AELIX Therapeutics website [+]<\/a><\/strong><\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"

AELIX Therapeutics<\/a>, a clinical-stage biotechnology company based in the Barcelona Science Park and\u00a0specialized in the discovery and development of immunotherapies for HIV infection,\u00a0announces that it has entered into a clinical research collaboration with Gilead Sciences<\/a>, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Both companies will jointly evaluatejointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.<\/p>\n

\u00a0<\/p>\n","protected":false},"author":1,"featured_media":53209,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-49517","post","type-post","status-publish","format-standard","has-post-thumbnail","category-uncategorized"],"acf":[],"yoast_head":"\nAELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"AELIX Therapeutics, a clinical-stage biotechnology company based in the Barcelona Science Park and\u00a0specialized in the discovery and development of immunotherapies for HIV infection,\u00a0announces that it has entered into a clinical research collaboration with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Both companies will jointly evaluatejointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-21T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-18T13:55:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16057066755fb523b3549ae.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"386\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure\",\"datePublished\":\"2018-10-21T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/\"},\"wordCount\":314,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/16057066755fb523b3549ae.jpeg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/\",\"name\":\"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/16057066755fb523b3549ae.jpeg\",\"datePublished\":\"2018-10-21T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/16057066755fb523b3549ae.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/16057066755fb523b3549ae.jpeg\",\"width\":800,\"height\":386},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/","og_locale":"en_US","og_type":"article","og_title":"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure - Parc Cient\u00edfic de Barcelona","og_description":"AELIX Therapeutics, a clinical-stage biotechnology company based in the Barcelona Science Park and\u00a0specialized in the discovery and development of immunotherapies for HIV infection,\u00a0announces that it has entered into a clinical research collaboration with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Both companies will jointly evaluatejointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2018-10-21T23:00:00+00:00","article_modified_time":"2020-11-18T13:55:36+00:00","og_image":[{"width":800,"height":386,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16057066755fb523b3549ae.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure","datePublished":"2018-10-21T23:00:00+00:00","dateModified":"2020-11-18T13:55:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/"},"wordCount":314,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16057066755fb523b3549ae.jpeg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/","url":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/","name":"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16057066755fb523b3549ae.jpeg","datePublished":"2018-10-21T23:00:00+00:00","dateModified":"2020-11-18T13:55:36+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16057066755fb523b3549ae.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16057066755fb523b3549ae.jpeg","width":800,"height":386},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-for-hiv-cure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=49517"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49517\/revisions"}],"predecessor-version":[{"id":53208,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49517\/revisions\/53208"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/53209"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=49517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=49517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=49517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}